Dianthus Therapeutics, Inc. Share Price & Technical Analysis
DNTH · $86.48 (-3.51%)
Healthcare / Biotechnology
$86.48
-3.51%
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-1% return in May, -11% avg return in past 3 year May month.
91% return in 2026, 97% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 30% | 4% | 56% | 3% | -1% | – | – | – | – | – | – | – | 91% |
| 25 | 0% | 0% | -16% | 23% | -19% | 6% | 11% | 16% | 68% | -10% | 28% | -5% | 102% |
| 24 | 84% | 31% | 18% | -28% | 2% | 17% | 16% | -4% | -4% | 3% | -15% | -9% | 109% |
| 23 | 42% | 44% | -3% | 0% | -15% | 21% | 8% | -8% | 16% | -11% | -4% | -9% | 81% |
| 22 | -27% | -5% | -8% | -51% | -19% | 2% | 31% | 11% | -20% | -10% | -16% | -66% | -178% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Neutral
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.72B
P/E ratio
—
52W high
$96.50
52W low
$16.64
Volume
4,59,383
Beta
0.09
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Dianthus Therapeutics, Inc. share price today?
- Dianthus Therapeutics, Inc. (DNTH) last traded around $86.48 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does DNTH have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for DNTH. Download the app for real-time alerts.
- How can I analyze Dianthus Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.